Recent Advances in Pulmonary Drug Delivery Systems

Dear Colleagues,

In recent years, pulmonary drug delivery systems have become a method of drug delivery that has attracted much attention. PDDSs refer to a special dosage form that is administered with a special device, such that a drug acts on the lungs and exerts local or systemic effects through the deep part of the respiratory tract. Pulmonary drug delivery systems have the advantages of being non-invasive, a quick onset, fewer local metabolic enzymes, and localized drug delivery, and are widely used in the treatment of respiratory diseases.

Despite several decades of research, the pulmonary delivery of biologics and high-dose active pharmaceutical ingredients, i.e., antibiotic, antibacterial, and antiviral drugs, is still challenging. There is still a significant gap between scientific research and clinical translation in enhancing lung deposition and bioavailability.

This Special Issue aims to collect the latest advances and state-of-the-art developments in the field of pulmonary drug delivery systems, including (but are not limited to) advanced drug delivery platforms for the treatment of respiratory diseases, in vitro/in silico/in vivo studies on the pulmonary drug delivery process and pulmonary deposition, the design of novel inhaler devices, studies relevant to potential lung toxicity and adverse effects of the excipients, and advanced delivery approaches for biopharmaceuticals. Notably, pulmonary drug delivery systems with high translational potential will be particularly preferred. Original research and review papers that reflect this topic’s status quo are warmly welcomed.

Prof. Dr. Chuanbin Wu
Dr. Xuejuan Zhang
Dr. Sha Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.